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Abstract 
Opioid medications are medicine’s best weapon against severe intractable pain, but 
prolonged use of these medications can be complicated by side effects like tolerance and mental 
clouding which, themselves, can be disabling. The present study examined the independent and 
combined effects of inflammatory pain and opioid medication on spatial memory for a well 
learned task in Sprague-Dawley rats.  The Hargreaves method was used to verify the pain state 
of the animals after complete Freund’s adjuvant injection and morphine treatment.  Whereas pain 
had little effect on spatial memory, morphine had profound detrimental effects that persisted 
beyond the analgesic effectiveness of the drug. However, morphine-induced cognitive deficits 
were absent when morphine was provided to animals in chronic pain. Also, analgesic tolerance 
was significantly attenuated in these animals. Taken together, these results suggest that chronic 
pain activates a neural mechanism that antagonizes the unwanted effects of opioids.     
 
 
 
 
 
 
Keywords:  radial maze, morphine, opioids, memory, pain, analgesic tolerance 
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Introduction 
Pain has been described as an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage (IASP, 1979).  It is 
useful to distinguish between acute and chronic pain. Acute pain serves a protective function by 
warning the organism of potential or actual injury that should be avoided or treated.  Acute pain 
leads to a withdrawal response and protective responses that prevent continued use of the injured 
body part to avoid further harm to that particular region.  Chronic pain, however, is longer in 
duration and may serve to motivate the organism to rest and attend to the injury during healing 
(Siegfried, Frischknecht, & De Souza, 1990; Hunt & Mantyh, 2001). When chronic pain outlasts 
healing, it can have a devastating impact on individual sufferers and society, leading to needless 
suffering, healthcare expenses, and lost productivity (Rosenblum, Marsch, Joseph, & Portenoy, 
2008).    
The reduction of pain and suffering is fundamental to good clinical practice. However, 
the clinical management of pain is not always a simple endeavor; the benefits offered by any 
interventions have to be weighed against the potential risks of treatment. In pharmacological pain 
management, the most effective pain relievers are derived from the opium poppy (papavre 
sativer). As a class, opioid drugs are capable of providing profound analgesic relief. The side 
effects of opioids include respiratory suppression, gastrointestinal slowing, addiction, and mental 
clouding.  Although these are very real and serious concerns, there is evidence that they are more 
common in “recreational” or illicit opioid use than in proper pain management. An approach 
using basic science is needed to better inform clinical decisions about opioid use. 
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Pharmacological Treatment of Pain 
Opioids and their receptors. Opioid medications are the best weapon against severe 
intractable pain. Opioid drugs, like morphine, codeine, hydrocodone, etc., act on opioid receptors 
in the CNS to produce their effects.  Opioid receptors consist of mu (µ)-, delta (δ)-, and kappa 
(κ)-opioid receptors (Harrison, Kastin, & Zadina, 1998). These receptors show a distinct pattern 
of expression and organization throughout the somatosensory systems, the limbic system, and the 
extrapyramidal system.  Mu and delta sites are concentrated in the more rostral areas of the CNS 
and appear to have complementary distributions (Sharif & Hughes, 1989).  Limbic structures, 
such as the neocortex, show predominately µ-receptor populations, with relatively fewer δ and κ 
sites (McLean, Rothmann, & Herkenham, 1986).  In more caudal areas, µ- and κ-receptors are 
more pronounced (Mansour, Khachaturian, Lewis, Akil, & Watson, 1988).   
All opiate receptors to date are believed to be members of the G-protein coupled receptor 
superfamily (Connor & Christie, 1999).  Members of this family show a conserved structure, 
with seven membrane spanning regions and exert their effects predominately by activating 
second messenger cascades (Connor & Christie, 1999).  In the case of opiate receptors, the 
effects of agonist binding are usually associated with the inhibition of cAMP production (Collier 
& Roy, 1974; Sharma, Nirenberg, & Klee, 1975), the inhibition of calcium influx (Brown & 
Birnbaumer, 1990), or the opening of an inward rectifying potassium current (DiChiara & North, 
1992), all of which are inhibitory with respect to the formation of an action potential by the 
postsynaptic neuron.   
The role of each receptor type has been dissociated to some degree.  Supraspinal 
analgesia has been attributed predominately to µ-receptors (Fu & Dewey, 1979).  Although δ-
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receptors have been shown to be involved in some supraspinal analgesia pathways, they are 
mainly localized in the medullary reticular formation (Jensen & Yaksh, 1986).  Agonists for each 
of the three receptor types produce antinociception at the spinal level, however, κ-agonists are 
unique in their suppression of mechanical nociceptive impulses; µ and δ appear to mediate 
thermal nociceptive signals (Schmauss, 1987).   
The presence of multiple receptor types predicts that a number of endogenous opiate 
peptides exist to serve as agonists at these receptors.  There are four known families of 
endogenous opioid peptides: enkephalins, β-endorphin, dynorphins, and endomorphins (Zadina, 
Hackler, Ge, & Kastin, 1997; Kandel, Schwartz, & Jessell, 2000).  Each of the opioid peptides 
has been found to have a distinct pattern of interaction with the receptor subtypes (Pasternack, 
1986; Leslie & Laughlin, 1993).  Beta-endorphin seems to show at least moderate affinity at 
these sites, but lacks high specificity (Hollt, 1986; Law, Loh, & Li, 1979).  The enkephalins 
seem to be the natural ligand of δ-receptors (Lord, Waterfield, Hughes, & Kosterlitz, 1977) and 
dynorphins show marked affinity and selectivity for κ-receptors (Chavkin, James, & Goldstein, 
1982; Corbett, Paterson, McKnight, Magnan, & Kosterlitz, 1982).  Endomorphin-1 and 
endomorphin-2 display high affinity and selectivity for the µ-receptor (Zadina et al., 1997).  
These endogenous opioid peptides activate the opioid receptors in response to a painful stimulus, 
thus regulating nociceptive transmission.  Morphine acts by mimicking the action of the 
endogenous opioids by inhibiting the firing of dorsal horn neurons responsive to nociceptive 
stimuli thus producing analgesia.         
Resistance to the utilization of opioids. Unfortunately, a hesitancy to utilize opioid 
therapy has developed which has led to inadequate pain management (Zenz, 1991; Cleary & 
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Backonja, 1996).  The number one reason physicians have become reluctant to prescribe opioid 
medications is fear of legal sanctions if the drugs wind up on the illicit market, a phenomenon 
called opiate shunting (Popenhagen, 2006).  Patients are also reluctant to use opioid therapy for 
reasons such as fear of side effects that include analgesic tolerance, withdrawal, and addiction.  
Although we do not propose to directly study opiate shunting in the clinical setting, we believe 
that studying the effects of opiates and their side effects will help to shed light on the clinical 
aspects of pain reduction with opioids.     
Pain’s Interaction with Opioids 
Pain and analgesic tolerance.  Although analgesic tolerance has been demonstrated in 
some clinical research there is growing evidence that tolerance is not a significant threat to good 
pain management. It has also been shown that analgesic tolerance develops rapidly in pain-free 
individuals, but fails to develop in people with chronic pain (Twycross, 1988; Melzack, 1991; 
Foley, 1993; Portenoy, 1994, Chen & Vaccarino, 2000). Other studies have shown that the 
occurrence of side effects such as analgesic tolerance, mental clouding, euphoria, respiratory 
suppression, and physical dependence seem to be reduced (Zenz, 1991; Forbes, 2006) or 
eliminated (Portenoy, 1996) when the patient is in pain.   
In the past two decades, animal studies have verified that pain can attenuate the 
development of analgesic tolerance in certain situations (Melzack, 1991; Vaccarino et al, 1997; 
Vaccarino, 1999).  The development of tolerance to morphine analgesia has been well 
established in models of phasic or brief, escapable pain (Mucha, Kalant, & Linseman 1979).  
However, the development of tolerance in models of persistent pain is less clear (Vaccarino et al, 
1997). Several models of persistent pain, e. g. subcutaneous (s. c.) formalin (Vaccarino & 
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Couret, 1993; Bardin, Kim, & Siegel, 2000), s. c. CFA (Chen & Vaccarino, 2000), and surgical 
pain (Ho, Wang, Liaw, Lee, H., & Lee, S., 1999) have been shown to attenuate tolerance 
development, while in other persistent pain models tolerance develops normally. The reasons for 
the discrepancies may be due to the type of pain model used, dose and route of morphine 
administration, or the presence or absence of pain during morphine injection (Cleary & 
Backonja, 1996).   
Pain and opioid reward.  Researchers have shown that pain attenuates the rewarding 
effect produced by morphine in both the conditioned place preference (CPP) and self 
administration models (Suzuki, Kishimoto, Misawa, Nagase, & Takeda, 1999; Narita, 
Kishimoto, Ise, Yajima, Misawa, & Suzuki, 2005).  It is believed that the pain state leads to a 
sustained activation of the κ-opioidergic system in the nucleus accumbens resulting in the 
suppression of the rewarding effects.  Researchers (Ozaki, Narita, Iino, Sugita, Matsumura et al, 
2002; Ozaki, Narita, Mizoguchi, Suzuki, & Tseng, 2003) have also shown that the rewarding 
effects induced by opioids have been absent under a neuropathic-pain state of a mouse or rat.  
Researchers have shown that mesolimbic dopamine neurons are involved in the brain 
mechanisms of reward and reinforcement (Wise & Rompre, 1989).  Ozaki et al (2002) believe 
that their findings suggest that this modification of morphine-induced place preference may 
result from a suppression of morphine’s ability to stimulate dopamine release in the nucleus 
accumbens due to a reduction in the µ-opioid receptor-mediated G-protein activation in the 
ventral tegmental area.   
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Mechanisms of Pain/Opioid Interaction 
 Taken together, the above findings suggest that the state of pain may alter the effects of 
opioid medications on the body.  It is important to discuss possible mechanisms for this 
phenomenon since the ability of pain to alter opioid effects is the basis for the hypothesis of the 
current study.  It has been reported that chronic pain can induce anxiety among other negative 
effects (Von Korff & Simon, 1996).  Many researchers (Sauro, Jorgensen, & Pedlow, 2003; 
Bomholt, Harbuz, Blackburn-Munro, G., & Blackburn-Munro, R., 2004) have concluded that 
stress results in a series of mechanisms that are aimed to protect the organism and restore 
homeostasis.  Our working hypothesis is that pain’s ability to activate the stress systems of the 
brain alters the body’s response to morphine.  This stress response includes both neural, (limbic 
and sympathetic nervous system activation) and a neuroendocrine response governed by the 
hypothalamus through the pituitary and adrenal glands, also called the hypothalamic pituitary 
adrenal (HPA) axis (Bomholt et al, 2004; Narita et al., 2006; Vierck, Acosta-Rua, Rossi, & 
Neubert, 2008).  The stress activates parvocellular neurons in the paraventricular nucleus of the 
hypothalamus, which releases corticotrophin-releasing factor (CRH) (Bomholt et al, 2004).  The 
release of CRH stimulates secretion of adrenocorticotropic hormone (ACTH) from the anterior 
pituitary (Jameison & Dinan, 2001).  
Research has shown that disruption of the HPA axis reduces the effects of pain on 
tolerance and this has been shown by the ability of hypophysectomy (Holaday, Dallman, & Loh, 
1979) and adrenalectomy  (Wei, 1973) to reverse pain’s effect on analgesic tolerance. 
Furthermore, Vaccarino et al (1997) demonstrated that pain failed to attenuate analgesic 
tolerance to morphine when adrenal steroid synthesis was inhibited by chronic metyrapone 
7 
 
administration because metyrapone blocks the elevation of corticosterone during stressful events 
without effecting basal corticosterone levels (Freo, Holloway, Kalogeras, Rapoport, & Soncrant, 
1992).  This finding implicated the stress induced elevation of corticosterone in the blockade of 
tolerance by pain.  Therefore, it is believed that stress is the key factor that is present with pain 
that prevents tolerance to opioids. 
 Activation of the stress response is a likely target for the mechanism of pain’s ability to modify 
opioid effects, since many stressful stimuli are capable of activating and modulating the 
endogenous opioid system upon which morphine acts (Watson & Mayer, 1981; Narita, Kaneko, 
Miyoshi, Nagumo, Kuzumaki, Nakajima et al., 2006). In many circumstances β-endorphin is 
released simultaneously with ACTH by the anterior pituitary. The simultaneous release of ACTH 
and β-endorphin is facilitated by the fact that they share the same pro-peptide molecule 
(proopioimelanocortin).  β-endorphin is released into the general circulation in physiologically 
significant amounts, a process that has been linked with stress-induced analgesia (Rubinstein, 
Mogil, Japon, Chan, Allen, & Low, 1996).  ACTH acts on the adrenal cortex to affect the release 
of glucocorticoids into the general circulation (Jameison & Dinan, 2001; Bomholt et al, 2004).   
Stress Effects on Opioid Receptors 
Narita et al (2006) investigated whether chronic pain could change opioidergic function 
in the amygdala.  It has been well documented that all three opioid receptor types are associated 
with anxiety and stressful situations (Kiristsy-Roy, Appel, Bobbitt, & Van Loon, 1986; Broom, 
Jutkiewicz, Folk, Traynor, Rice, & Woods, 2002; Pfeiffer, Brantl, Herz, & Emrich, 1986).  
Narita et al (2006) found a decrease in the stimulatory effect of a µ- and δ-opioid receptor 
agonist and an increase in the G-protein activation by a κ-opioid receptor agonist following CFA 
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injection.  Zubieta, Smith, Bueller, Xu, Kilbourn, Jewett et al (2001) has also shown, via positron 
emission tomography, a reduction in µ-opioid receptor availability in human subjects during 
sustained pain.  Narita et al (2006) concluded from his findings that sustained pain increases the 
release of endogenous opioids interacting with µ-opioid receptors in the amygdala and this 
results in the internalization and recycling of µ-opioid receptors.  The reduction in µ-opioid 
receptors as a result of release of ACTH in the HPA axis alters the effects of opioids on the 
organism.  Therefore, the organism will be in a stressful state as a result of the pain, which will 
reduce the amount of µ-opioid receptors resulting in a modification of opioidergic effects.  One 
possibility is that the deleterious effects of morphine on cognitive functioning can also be 
modulated by the stressful nature of pain through this particular mechanism, similar to how 
stress modulates opioid tolerance and opioid reward. 
While Narita et al (2006) emphasize the importance of the release of ACTH in the HPA 
axis as a mechanism for pain’s ability to modify opioids’ effects, other researchers believe that 
the release of β-endorphin in the HPA axis is the mechanism for altering opioidergic effects.  
The relative analgesic versus endocytosis or “RAVE” theory emphasizes the effect of agonist 
activity and receptor endocytosis on receptor mediated signaling (Finn & Whistler, 2001).  It is 
believed that agonist activity and receptor endocytosis have opposing effects on the ability of the 
receptor to signal.  It has been shown that morphine has a high RAVE value due to its inability to 
promote receptor desensitization and endocytosis (Whistler, Chuang, Chu, Jan, & von Zastrow, 
1999).  However, endorphins and opioid drugs with lower abuse potentials induce receptor 
desensitization and endocytosis, resulting in a lower RAVE value (Finn & Whistler, 2001). 
These two observations have led researchers to suggest that drugs with a high RAVE value have 
a tendency to produce adverse effects due to prolonged signaling that leads to mu receptor 
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sensitivity.  Researchers have shown that a reduction in prolonged signaling of drugs with high 
RAVE values helps reduce the development of side effects (Finn & Whistler, 2001).  He, von 
Zastrow, & Whistler, J. L. (2002) have also shown that the development of tolerance was 
attenuated by the simultaneous injection of endogenous ligands and morphine. Therefore, 
another possible mechanism for pain’s effect on opioid analgesia and reward is that the stress 
induced by the painful stimulus will activate the HPA axis causing a release of the endogenous 
opioid, β-endorphin.  This release of β-endorphin and administration of morphine will result in a 
reduction of the adverse effects of prolonged signaling induced by morphine.  Through this 
mechanism, it is possible for pain to modify the deleterious effects of morphine and possibly 
minimize the adverse effects of opioid medications.            
Opioid Effects on Cognition 
Cognitive functioning incorporates a wide variety of mental activities.  Cognition has 
been defined as the “brain’s acquisition, processing, storage and retrieval of information” 
(Lawlor, 2002).  Domains of cognition include attention, concentration, simple recall, working 
memory, verbal memory, and executive function.  Clinical research has shown that ingestion of 
opioid drugs is detrimental to cognitive function (Forbes, 2006).  According to Zacney (1995), 
the negative effects of opioids are most pronounced in “healthy volunteers” who show delayed 
reaction, confusion, and a host of other specific dose-dependent deficits.   In pain patients, the 
sedation and mental clouding experienced is limited to a few days after the initiation or 
escalation of opioid dosing (Forbes, 2008).   
While there are a number of basic science studies demonstrating the effects of opioids on 
pain-free animals, there is a paucity of studies on the effects of opioids on animals in chronic 
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pain.  Opioids have been shown to disrupt both acquisition and recall of a variety of learned 
responses (McGaugh, 1983).  It has also been shown that acute morphine disrupts operant 
responding and chronic morphine delays acquisition of simple and cued operant responses 
(Wang, Dong, Cao, & Xu, 2006).  Zheng, Li, Yang, & Sui (2002) reported that chronic morphine 
delays acquisition in the Morris water maze, but this finding has not been replicated (Wang et al, 
2006) 
Pain’s Effects on Cognition 
Equally clear is the fact that pain, especially severe pain, disrupts cognition.  People 
experiencing pain show deficits in attention and reaction time (Zenz, 1991; Lorenz, Beck, & 
Bromm, 1997), and more complex tasks such as memory tasks (Crombez, Eccleston, Baeyens, & 
Eelen, 1996; Lorenz et al, 1997; Eccleston, Crombez, Aldrich, & Stannard, 1997).  It has been 
demonstrated that formalin pain (Ceccarelli, Scaramuzzino, & Alosi, 2001), bowel pain 
(Millecamps, Etienne, Jourdan, Eschalier, & Ardid, 2004), and neuropathic pain (Benbouzid, 
Choucair-Jaafar, Yalcin, Waltisperger, Muller, Freund-Mercier et al., 2007) can disrupt approach 
and exploration of novel objects in experimental animals.  Although some authors argue that 
their observations demonstrate a disruption of working and reference memory, the deficits in 
approach behavior may be due to pain’s anxiogenic properties since some of pain’s effects are 
reversed by administering anxiolytics and antidepressants (Benbouzid et al, 2007).  Therefore, it 
is not clear if the deficits in performance may be due to anxiety rather than memory errors.  Thut, 
Hermanstyne, Flake, & Gold (2007) have also shown that pain, e.g. temporal mandibular joint 
(TMJ) pain, can disrupt operant responding for food, however, this finding is potentially due 
more to the avoidance of TMJ pain rather than disruption of memory for the response.  While 
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these models attempt to test the effects of pain on memory, they fail to provide a valid measure 
to adequately assess memory performance.        
Hypothesis and Specific Aims 
While opioid medications are the best pharmacological weapon against severe pain, the 
utilization of opioid medications to alleviate chronic pain has been limited due to the potential 
for undesirable side effects and the tendency for these drugs to surface in the illicit drug market. 
The possibility of analgesic tolerance and deficits in cognition that accompany opioid ingestion 
often hinders clinicians and patients from utilizing opioid therapy (Melzack, 1991; Ersek, 
Cherrier, Overman, & Irving, 2004).  Fortunately, the positive and negative effects of opioids are 
separable to some degree, as evidenced by the ability of opioids to achieve analgesia without 
euphoria or significant cognitive dysfunction in some pain patients (Zenz, 1991; Forbes, 1996). 
Clearly the presence of pain can alter the time course of opioid reward and analgesic tolerance 
development. However, the interaction between the effects of opioid medications and pain on 
learning and memory are unclear.  A better understanding of this interaction will improve the 
clinical management of long term pain.  
 This project examined the independent effects of pain and morphine as well as the interaction 
between pain and opioids on recall in the radial maze. The central hypothesis is that the stress 
response induced by pain modifies the deleterious effects of acute and chronic opioids on 
working and reference memory.  This central hypothesis was examined in three specific ways.   
First it was important to determine the effects of pain on working and reference memory 
errors in a dose dependent fashion.  Although this was a novel attempt at directly testing the 
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effect of pain on memory, it was believed that pain would impair memory performance by 
increasing the amount of errors across all 5 days of testing.  Also, it is believed that tolerance to 
pain’s effect on memory would not develop.  
The next step was to determine the effects of morphine on working and reference 
memory errors.  Acute morphine administration was expected to increase both working and 
reference memory errors relative to the pain- and morphine-free control group.   Chronic 
morphine administration was also expected to lead to an increase in working and reference 
memory errors.     
Finally, the current study determined whether pain attenuates the deleterious effects of 
opioids on working and reference memory errors.  It was believed that pain would activate a 
stress response in the HPA axis that would modify opioids’ negative effects, thus reducing the 
amount of working and reference memory errors.  Also, animals that were in pain were expected 
to show continued analgesia in response to morphine injection while those not in pain would not 
show tolerance to the analgesic effects.  
In order to achieve proper clinical pain treatment, it would be beneficial to find ways to 
minimize the side effects that physicians and patients fear while maximizing analgesia.  By 
achieving this goal, physicians and patients will become more confident in opioid medications, 
thus becoming more likely to utilize opioid therapy for pain management.  This current design is 
will prove to be valid as a model for the study of analgesia, cognition, and other outcome 
measures relevant to pain management.  As a result, this model will be an improvement over the 
typical approach of studying these variables independently and help to develop a pharmaceutical 
solution to increase analgesia while curtailing cognitive impairment.       
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Methods 
In order to test the hypotheses mentioned above, a factorial design was conducted that 
crosses 2 levels of pain (0, 70 ml CFA) x 2 doses of morphine (0, 10 mg/kg).  Table 1 outlines 
the entire factorial design.  This design allows for comparisons of the effects of pain and 
morphine alone on cognition and analgesia as well as the interaction between pain and morphine 
on these factors. 
Animals   
Forty male Sprague-Dawley rats, housed in pairs, were maintained at 80-85% free 
feeding weight and were given free access to water (Floresco, Seamans, & Phillips, 1997; 
Schrott, Franklin, & Serrano, 2008).  Each rat weighed between 200 and 225g at the start of 
training and the restricted diet was maintained until the end of the project.  These animals were 
on a 12 hour light cycle with all the experiments occurring in the first 6 hours of the dark cycle.   
Materials and Apparatus 
Drugs.  Morphine Sulphate (Paddock Laboratories, USA) was dissolved in physiologic saline 
and administered in a volume of 1ml/kg subcutaneously (s.c.) on the dorsal surface of the body.  
Equal volume saline was injected in control subjects. Pain was elicited by s.c. injections of 
complete Freund’s adjuvant (CFA, Sigma, USA) 100% concentration subcutaneously (s.c.) into 
the plantar surface of the left hindpaw.  
Radial Maze.  An eight-arm radial maze constructed of ABS plastic floors and Plexiglas® walls 
was used to assess cognitive functioning.  This maze consists of an octagon center, which is 
where the animal begins.  There are 8 identical arms that extend from the center start box with a  
14 
 
Table 1.  Factorial Design 
 Pain Severity- Dose CFA (µl) 
 
Level of Analgesia 
Dose of Morphine 
(mg/kg) 
 0 70 
0 No Pain/No Morphine Pain/No Morphine 
10 No Pain/Morphine Pain/Morphine 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
bait cup at the end of each arm opposite the opening of the arm.  The bait cup is 2cm from the 
floor so the food is not visible from the arm opening.  The baited arms consisted of sugar-coated 
cereal (Kellogs, USA) as a reward.   
The experiment consisted of habituation, shaping, and training of the animals (Spritzer, Gill, 
Weinberg, & Galea, 2008).  On day 1, pairs of animals received two 5-minute habituation trials 
where nine small pieces of cereal are spread throughout the maze.  The animals were allowed to 
freely roam the maze and eat the cereal.  This was followed by two 5-minute shaping trials, 
where the individual rats must retrieve pieces of cereal placed in the food cups at the end of 
every arm.  The training trials consisted of two 5-minute trials daily.  In the first “reminder” trial, 
animals were allowed 5 minutes to obtain cereal bait from 4 randomly selected arms and these 
same 4 arms were baited for every training trial.  The remaining 4 arms were blocked by 
guillotine barriers at their entrances.  During the second trial, the same four arms were baited but 
access to all arms was allowed.  The behavior of the animals was video recorded and analyzed 
using AnyMaze software.  During the second trials, working memory errors are defined as re-
entry to arms previously entered in the trial and reference memory errors are defined as entry 
into unbaited arms (Hodges, 1996; Floresco et al, 1997; Schrott et al, 2008). The total distance 
traveled down each arm was assessed.  Animals were trained until they obtain the four rewards 
while making 1 or fewer incorrect arm entries.  Animals who did not reach this asymptotic level 
of performance by 20 trials were eliminated from the study.   
Hargreaves Test.  Animals were placed in Plexiglas® enclosures with glass floors (20cm2) 
suspended 30cm from the table top and allowed to habituate for 30 minutes.  The area of the 
animal’s hindpaw targeted by the s.c. injections was stimulated from below using a halogen heat 
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source.  The latency to produce a nocifensive withdrawal response was used to measure 
analgesia.  The other hindpaw was also tested as the control paw.   
Procedure 
The day following the establishment of criterion performance in the working and reference 
memory radial maze task, the animals were randomly assigned to a pain severity x morphine 
dose condition.  Baseline thermal withdrawal latencies were measured and the animals received 
s.c. injections of 0 or 70μl CFA.   
To establish the pain state of the subjects, thermal withdrawal latencies were measured 24 hours 
post-CFA injections (pre-morphine baseline). For the next 5 days, radial maze trails continued as 
before except that animals received s.c. injections of morphine (10 mg/kg) or saline 30 minutes 
prior to testing in the radial arm maze and testing in the maze was followed immediately by 
thermal withdrawal testing to assess the effects of morphine/saline treatment on pain.   
Both morphine and tonic inflammatory pain can reduce locomotion and can confound the 
dependent measures in this study since they depend in part on locomotor ability.  The dependent 
measures used in the current study was not based on latency to obtain reward, but rather data 
from arm entries which are more resistant to locomotor effects.  The AnyMaze® software was 
used to generate a measure of running speed which can be compared across conditions as 
measures of locomotor impairment.  This measurement helped to determine the relevance of 
locomotor effects. 
Control Study. Morphine may produce a state of nausea in rats leading to a behavior 
termed pica (Takeda et al, 1993).  Mitchell, Wells, Hoch, Lind, Woods, & Mitchell (1976) 
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described pica as an illness-response in rats characterized by eating non-nutritive substances, 
such as the cage bedding, since they are incapable of emesis.  When pica is present, rats are 
unlikely to engage in behavior for a food reward – thus if animals receiving morphine show 
decreased performance in the maze, it may be due to cognitive disruption or lack of motivation.  
However, some researchers (Kelley, Bakshi, Haber, Steininger, Will, & Zhang, 2002) have 
shown that opioids selective for the µ-opioid receptor can actually increase food uptake and 
show improvement in performance for behaviors rewarded with highly appetitive foods 
especially for hedonic foods.  Due to this potential issue with pica, a control study was conducted 
to determine whether animals that are administered morphine eat more or less food than animals 
without morphine.  Animals were injected with either 10 mg/kg of morphine or saline.  The 
animals were then placed in an open field and the amount of food consumed by both conditions 
was recorded. 
 
 
 
 
 
 
 
 
18 
 
Results 
All animals included in the study reached criterion performance in the radial maze task in 4 - 15 
days. Six animals were excluded from testing when they failed to reach criterion performance by 
the 15 day cut-off and were replaced with additional subjects to maintain sample size. All data 
were examined for statistical outliers and none were found; no data were excluded from analysis. 
All subsequent analyses were performed using SPSS for Windows (version 16.0) with the 
probability of a Type I error set at 0.05. The data from memory errors and locomotor speed were 
analyzed using separate 2 x 2 x 6 mixed factorial ANOVA with Pain (0, 70 μl) and Morphine 
Dose (0, 10 mg/kg) serving as between subjects variables and Trials (baseline and Days 1-5) 
serving as a within-subjects variable; analgesia was analyzed in a 2 x 2 x 7 Pain (0,   70 μl) X 
Morphine Dose (0, 10 mg/kg) X Trial (baseline, post-CFA, Days 1-5) mixed factorial ANOVA.  
All significant 3-way interactions were followed by planned analysis of the interaction contrast 
for pain x analgesia at every time point. Dunnett’s test was employed to control the family-wise 
error rate as we compared the treatment groups to the no pain/no morphine control. Significant 
results discussed below indicate p < 0.05 for the comparison. 
Analysis of Working and Reference Memory 
Working and reference memory data from the radial maze test trials is summarized in 
Figure 1 and Figure 2 respectively.   The 3-way interaction indicates that the animals in the no 
pain/morphine condition displayed significantly more errors than the no pain/no morphine 
control group [F (6, 108) = 17.85, p < 0.05].  Dunnett’s test subsequently revealed that the no 
pain/ morphine group displayed significantly more errors than the no pain/no morphine control 
on days 2-5.  
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Figure 1.  Mean (+/- SEM) number of arm re-entries for 5 days following induction of an 
inflammatory injury (pain groups) or no injury (control groups).  * Indicates the No 
Pain/Morphine group was significantly different from the No Pain/No Morphine group (p < 
0.05). 
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Figure 2.  Mean (+/- SEM) number of incorrect arm entries for 5 days following induction of an 
inflammatory injury (pain groups) or no injury (control groups).  * Indicates the No 
Pain/Morphine group was significantly different from the No Pain/No Morphine group (p < 
0.05). 
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Analysis of Locomotor Slowing 
Locomotor data from the radial maze experiment is presented in Figure 3. Again a 3-way 
interaction was conducted and revealed significantly slower navigation speeds for both groups 
receiving morphine injections when compared to the two groups without morphine injections.  
Dunnett’s test was performed on all significant 2-way interactions, indicating both groups 
receiving morphine navigated the maze at slower speeds than the no pain/no morphine control on 
days 1 – 5. No other significant effects were observed. 
Analysis of Analgesia 
Thermal withdrawal threshold testing data are summarized in Figure 4 which indicated 
that CFA injection produced a pronounced thermal hyperalgesia that was acutely reversed by 
morphine administration. A significant 3-way interaction [F (6, 108) = 27.46, p < 0.05] was 
observed.  Subsequent analysis revealed 4 significant findings:1) no difference in baseline 
sensitivity was noted; 2) 24 hours after injury, both groups that received CFA were significantly 
hyperalgesic; the pain/no morphine group remained hyperalgesic throughout the 5 days of testing 
and 3) on days 1-4 both groups receiving morphine injections showed significant elevations in 
their withdrawal threshold, but 4) on day 5, the withdrawal threshold for the pain/morphine 
group was significantly elevated from the no pain/no morphine control. 
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Figure 3.  Mean (+/- SEM) speed in the radial maze for 5 days following induction of an 
inflammatory injury (pain groups) or no injury (control groups).  * Indicates that the No 
Pain/Morphine group and Pain/Morphine group were significantly different from the No Pain/No 
Morphine group (p < 0.05). 
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Figure 4.  Mean (+/- SEM) thermal withdrawal latency.  * Indicates the groups receiving CFA 
differed significantly from the No Pain/No Morphine group (p < 0.05).  ** Indicates all groups 
differ significantly from the No Pain/No Morphine group (p < 0.05).  *** Indicates the Pain/No 
Morphine and the Pain/Morphine groups differ significantly from the No Pain/No Morphine 
group (p < 0.05) 
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Analysis of Control Study 
Data from the separate free feeding study revealed that the morphine and saline control 
groups consumed all the available food (4x the amount in the maze during test trials) within the 
10-minute time period, resulting in the same average weight of food consumed and no 
variability, rendering the calculation of t unnecessary. 
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Discussion 
Despite resulting in produced significant inflammation and thermal hyperalgesia, CFA 
administration at the dose employed in the current study failed to impact working and reference 
memory errors on an acquired radial maze task. This was surprising given reports of significant 
reductions in cognitive performance following rodent models of collitus (Millicamps, et al. 
2004), formalin-induced pain (Ceccarelli et al., 2001), and neuropathy (Benbouzid et al., 2007). 
The difference in outcomes may be due to the pain model employed or the sensitivity of the 
different memory tasks employed to the effects of CFA-pain. 
Not surprisingly, morphine administered to pain-free animals resulted in increased 
memory errors on our task. This wholly expected finding is in keeping with numerous reports 
that acute (Ragozzino & Gold, 1995; Li, Wu, Pei, & Xu, 2001) and chronic (Spain and Newsom, 
1989; Miladi-Gorji, Rashidy-Pour, & Fathollahi, 2008; Wang et al., 2006) opioid administration, 
as well as opioid withdrawal (Ma, Chen, He, Zeng, & Wang, 2007) impair performance in a 
variety of rodent models of learning/memory. Importantly, when the same dose of morphine that 
lead to a significant increase in memory errors was administered in the presence of CFA-induced 
inflammatory pain, there were no disruptions of memory observed. The relationship between 
pain and morphine has not been well studied. In the only other examination of the interaction 
between the cognitive effects of pain and morphine identified for this review, similar results 
were obtained (Millecamps, et al., 2004).  The researchers induced colitis in rats and visual non-
selective, non-sustained attention was assessed.  Chronic inflammatory pain produced deficits in 
the task, which were attenuated by effective analgesic treatment.      
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Explanations for Memory Impairment 
The increase in working and memory errors observed in pain-free animals may be due to 
a variety of factors, including locomotor slowing (Grecksch, Bartzsch, Widera, Becker, Hollt, & 
Koch, 2006) and alterations in appetite that have been observed following opioid administration 
(Takeda, Hasegawa, Morita, & Matsunaga, 1993). The reversal of opioid-induced cognitive 
effects and the attenuation of analgesic tolerance contrasts with the inability of pain to reverse 
morphine-induced locomotor slowing. This is consistent with other reports of locomotor slowing 
in the presence of opioids across several experimental designs (Timar, Gyarmati and Furst, 
2005). The observation that pain interferes with some opioid effects leaving others in tact is 
intriguing because it suggests that different neural mechanisms exist for each of these outcomes. 
We suggest that locomotor slowing does not account for the increase in errors in pain-free 
animals because slowing was also observed in CFA + morphine treated animals, yet this group 
made few errors. 
Likewise, decreased appetite is an unlikely explanation for the mistakes made by 
morphine-only animals because morphine did not alter food intake relative to saline when 
separate groups of animals were presented with the food stimulus used in the maze. There was 
no difference between the morphine group and saline group in terms of food consumed.  
Therefore, one can assume that morphine at the doses used in this study does not cause an 
avoidance behavior towards food and the poor performance was due to cognitive deficits rather 
than some other confounding factor.           
Biological Underpinnings.  Alternatively, morphine treatment could influence radial 
maze errors through direct or indirect effects on attention, spatial memory, or response selection 
circuitry. Two possible sites of action are the caudate nucleus (CN) and locus coeruleus (LC). 
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The CN has been found to mediate a hippocampal-independent learning circuit that is essential in 
reference memory performance (Packard & White, 1990). For example, Packard & White (1990) 
trained animals in a version of the radial maze task similar to the current task where they baited 
the same 4 arms on each trial.  Packard & White (1990) demonstrated that rats with CN lesions 
were impaired on radial maze tasks that assess reference memory, while working memory 
performance was unaffected by CN lesions in the task.  Other researchers were able to 
demonstrate opposite findings in radial maze tasks that assess working memory with lesions in 
the hippocampus disrupting working memory performance and CN lesions having no effect on 
working memory (Packard, Hirsh, & White, 1989).  As one of the three subdivisions that make 
up the striatum (Kandel, 2001), the CN receives afferent fibers directly from all areas of the 
neocortex (Hokfelt and Ungerstedt 1969), the thalamus, raphe nuclei, and amygdala 
(Villablanca, 2010). The CN projects to the frontal cortex (via the thalamus) and, downstream, it 
projects to the globus pallidus, thalamus, and substantia nigra pars reticulata (Villablanca, 2010).  
The striatum as a whole has been implicated by many researchers as a neuroanatomical structure 
that mediates the addictive and dependence-producing properties of morphine (Glick, Cox, & 
Crane, 1975).  Many behavioral findings have supported the idea that morphine inhibits 
dopaminergic activity in the striatum in general (Lal, O'Brien, & Puri, 1971; Puri & Lal, 1973; 
Gianutsos, Drawbaugh, Hynes, & Lal, 1974; Kuschinsky & Hornykiewicz, 1974), and the CN in 
particular (Datta, Thal, & Wajda, 1971). For instance, the caudate nucleus is believed to be 
responsible for coordinating motor activity in rats (Elliot, 1963).  However, after a large dose of 
morphine, rats have been shown to become immobile or catatonic due to the inhibition of the 
caudate nucleus (Datta et al., 1971).  Also, Lal et al. (1971) used Haloperidol to block dopamine 
receptors and found that this drug exacerbated withdrawal symptoms in rats and humans.  Based 
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on these research findings, evidence has been provided for the inhibition of the striatum as a 
result of morphine administration.   
While CN inhibition resulting from opioid administration can explain reference memory 
impairment in pain-free animals, suppression of LC activity can be a more global explanation of 
both working and reference memory impairment following opioid use.  The LC contains 
noradrenergic neurons and is responsible for maintaining vigilance and responsiveness to 
unexpected stimuli (Kandel, 2001).  Researchers have determined that the LC has an excitatory 
influence on both the striatal and limbic dopamine systems (Lategan, Marien, & Colpaert, 1990).  
Despite the LC excitatory influence on striatal and limbic systems, research has shown that 
morphine administration decreases LC activity (Korf, Bunney, & Aghajanian, 1974, Millan, 
2002), resulting in a dose-dependent range of effects from inattention, sedation and catatonia 
(Aston-Jones, Gonzalez, & Doran, 2005).  It is important to note that the LC has two modes of 
activity which are called phasic and tonic (Aston-Jones & Cohen, 2005).  Aston-Jones & Cohen 
(2005) have shown support for the phasic LC activation as a facilitator of task performance, 
while tonic activity results in a disengagement from the current task or poor performance.  
Aston-Jones & Cohen (2005) have described the relationship between the task performance and 
LC activity as a Yerkes-Dodson relationship.  They believe that performance is poor at very low 
levels of tonic activation due to drowsiness and lack of arousal.  Performance is best when there 
is moderate tonic activation and sufficient phasic activation.  However, high levels of tonic 
activation with low phasic activity will result in poor performance as well.  Based on this theory, 
morphine administration may decrease phasic activation and tonic activation of the LC, resulting 
in a disengagement from the task and lack of arousal that leads to poor performance in the radial 
maze.  This decrease in LC activity is due to mu-receptor gated potassium currents which 
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decrease the firing rates of noradrenergic cells in the LC (DiChiara & North, 1992). This 
decrease in LC activity results in a decrease in striatal activity leading to the exacerbated 
withdrawal symptoms and catatonia associated with morphine administration.  Also, the decrease 
in LC activation results in reduced stimulation of cortical circuits leading to inattention and other 
cognitive deficits.  This inhibition of the LC results in a decrease in striatal activity in 
conjunction with inattention as a result of understimulated cortical circuits offers a potential 
explanation for the observed increase in errors in our animals.  
Pain, on the other hand, increases the activity of the LC (Jones, 1991; Millan, 2002; 
Pertovaara, 2006).  This increase in activity can lead to the possible activation of striatal 
dopamine system (caudate nucleus) and cortical circuits resulting in the attenuation of side 
effects seen with the interaction of pain and morphine administration.  This theory could possibly 
explain how pain can modify morphine-induced analgesia and cognitive impairments.  The CFA 
pain stimulates the LC, which increases the activity of the striatal dopamine system and cortical 
circuits, resulting in a reversal of cognitive impairment and a delay in the development of 
analgesic tolerance.  This increase in LC activity could be an increase in both phasic and tonic 
activation of the LC, which leads to the optimal performance that was described earlier in 
relation to the Yerkes-Dobson relationship of Aston-Jones & Cohen (2005).  The pain stimulus 
could possibly result in an adequate increase in both the phasic and tonic stages of the LC to 
increase performance and reverse the poor performance in the radial maze that was observed 
with the morphine-only animals in the current study.  
Replication of Analgesia Studies 
Importantly, pain not only interacts with morphine-induced cognitive effects, but also 
with analgesia. Acutely, morphine produced analgesia in both pain-free and CFA injected 
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animals. By the fifth day of chronic morphine administration, analgesic tolerance was evident in 
pain-free animals, but absent in animals suffering from chronic pain. This replicates previous 
findings that the presence of formalin (Vaccarino et al., 1997), surgical pain (Ho et al., 1999) and 
CFA pain (Chen & Vaccarino, 2000) attenuates the development of analgesic tolerance.  
Conclusions 
Taken together, these findings suggest that pain activates neural mechanisms which 
antagonize opiate effects. This interaction is not surprising given that pain activates a global 
stress response, which includes activation of endogenous mechanisms of pain control. The 
endogenous opiates released in response to stress participate in multiple feedback circuits 
regulating the stress response.  
Furthermore, these data have relevance to the clinical management of pain. A general 
reluctance to prescribe opioids on the part of clinicians has been discussed in the literature (Zenz, 
1991; Cleary & Backonja, 1996; Popenhagen, 2006). Reasons for this reluctance include fear of 
the development of tolerance, dependence, and the occurrence of side effects like mental 
clouding. Attitudes about opioid pain management are beginning to change; however, there is a 
need for better basic science to inform clinical practice. Here we present data that demonstrate 
the dangers of tolerance and cognitive disruption that exist in addictive behavior do not always 
apply to clinical pain management.  
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